100 International Drive
Portsmouth, NH 03801
Main Line: 603.929.5078
Toll-Free: 888.731.7322 x8200
A new legislative biennium in Vermont means further changes to the Vermont Gift Ban (18 V.S.A. §4631a) as well as the aggregate spend reporting requirements (18 V.S.A.§4632). On May 6, 2011, the Vermont House and Senate approved Senate Bill 104 which is currently awaiting the signature of Governor Shumlin. See the MediSpend Legislative Watch for a summary of how the revised legislation will affect Pharmaceutical and Medical Device Manufacturers.
On February 18, 2011, a bill was submitted (House Paper No. 530) to "Make Certain Prescription Drug Disclosure Laws Consistent with Federal Law." Specifically, House Paper No. 530 seeks to repeal 22 MRSA §2698-A which establishes the requirement for pharmaceutical manufacturers to report marketing costs, including certain expenditures on health care providers. If passed, the legislation would eliminate Maine's aggregate spend reporting requirements. Presumably, the bill's sponsors recognize the redundancy in reporting requirements with the implementation of the Federal Sunshine Act.
The bill was referred to the Committee on Health and Human Services on February 18, 2011 and has yet to be reported... Read more..